For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 24,614 | |||
| General and administrative | 9,783 | |||
| Total operating expenses | 34,397 | |||
| Operating loss | -34,397 | |||
| Other income, net | 1,659 | |||
| Total other income, net | 1,659 | |||
| Loss before income tax expense | -32,738 | |||
| Income tax expense | 28 | |||
| Net loss | -32,766 | |||
| Unrealized gain on marketable securities | 27 | |||
| Comprehensive loss | -32,739 | |||
| Basic EPS | -0.7 | |||
| Basic Average Shares | 46,980,777 | |||
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)